FATE News and Press, Fate Therapeutics Inc. From 03/05/25

2025-03-05 16:51:06 ET More on Fate Therapeutics Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap Seeking Alpha’s Quant Rating on Fate Therapeutics Historical earnings data for Fate Therapeutics Financial information for...

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE Completed Type D Meeting with FDA to Enable FT819 Off-the-Shelf CAR T-cell Dose Expansion in Additional B Cell-mediated Autoimmune Diseases ...

BBB Foods Inc. Class A (TBBB) is expected to report $0.02 for Q4 2024 Beamr Imaging Ltd. (BMR) is expected to report for quarter end 2024-12-31 Transportadora de Gas del Sur SA TGS (TGS) is expected to report $0.5 for Q4 2024 Henkel AG & Co. KGAA ADR (HENKY) is expected to report ...

2025-02-26 10:52:02 ET Summary Allogene Therapeutics is developing allogeneic CAR-T cells for cancer and autoimmune diseases, offering off-the-shelf therapies that reduce costs and treatment times. Cema-cel, Allogene's leading product, shows promise in first-line treatment of larg...

Grupo Aeroportuario del Sureste S.A. de C.V. (ASR) is expected to report $5.54 for Q4 2024 Zoom Communications Inc. (ZM) is expected to report $0.66 for Q4 2025 Toro Corp. (TORO) is expected to report for Q4 2024 Apple Hospitality REIT Inc. (APLE) is expected to report $0.31 for Q4 20...

2025-02-04 19:41:27 ET Summary Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients. Their pipeline has 3 interesting Phase 1 candidates for SLE, Solid Tumors, and B-cell lymphoma. But in my vie...